This month, researchers at the University of Washington are set to begin a clinical trial that will administer the chemical rapamycin to middle-aged pet dogs. Their hope is that it will delay key markers of the aging process, laying the foundation for rapamycin and its derivatives to become the first legitimate anti-aging drug. Once considered a quack…
© 2025 Hedgeye Risk Management, LLC
Substack is the home for great culture